bioAffinity TechnologiesBIAF -1.48%44 Days Inventory is 6.48 as of Mar. 2026, which is 114% above its 10-year median of 3.03. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 178 Medical Diagnostics & Research companies, bioAffinity Technologies ranks better than 96.07% on this metric.
The historical rank and industry rank for bioAffinity Technologies's Days Inventory or its related term are showing as below:
BIAF'
s Days Inventory Range Over the Past 10 Years
Min: 1.4 Med: 3.03 Max: 2190
Current: 4.82
During the past 6 years, bioAffinity Technologies's highest Days Inventory was 2190.00. The lowest was 1.40. And the median was 3.03.
BIAF's Days Inventory is ranked better than 96.07% of 178
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.88
vs BIAF: 4.82
Inventory Turnover measures how fast the company turns over its inventory within a year.
bioAffinity Technologies's Inventory Turnover for the
three
months ended in Mar. 2026 was 14.08.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
bioAffinity Technologies's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.05.
bioAffinity Technologies (NAS:BIAF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
bioAffinity Technologies's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
bioAffinity Technologies's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
bioAffinity Technologies Days Inventory Related Terms
bioAffinity Technologies Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIAF vs NDRA, ISPC, ADVB: Days Inventory Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Days Inventory distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a Days Inventory of 6.48 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on bioAffinity Technologies and its competitors. This is 114% above median its historical median of 3.03. Over the past decade, bioAffinity Technologies' Days Inventory has ranged from 1.40 to 2,190.00. According to the industry distribution chart, bioAffinity Technologies ranks #7 out of 178 companies in the Medical Diagnostics & Research industry, placing it in the top 3.9%.
Is bioAffinity Technologies' Days Inventory too high?
bioAffinity Technologies' current Days Inventory of 6.48 is 114% above median its 10-year median of 3.03. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 2,190.00. The Medical Diagnostics & Research industry median Days Inventory is 68.88. bioAffinity Technologies' value of 6.48 is 90.6% below this industry median. Based on the distribution chart, bioAffinity Technologies ranks #7 out of 178 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Days Inventory compare to NDRA and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #7 out of 178 companies for Days Inventory. This places bioAffinity Technologies in the top 4% of its industry — outperforming the majority of peers. The industry median Days Inventory is 68.88. bioAffinity Technologies' value of 6.48 is 90.6% below this benchmark. Historically, bioAffinity Technologies' own Days Inventory has ranged from 1.40 to 2,190.00 over the past decade. While the company's 10-year median is 3.03 vs. the industry median of 68.88, bioAffinity Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 68.88, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioAffinity Technologies's current Days Inventory of 6.48 is 90.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 68.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current Days Inventory is 6.48, which is 114% above median its own 10-year median of 3.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current Days Inventory is 6.48, which is 114% above median its 10-year median of 3.03 and 90.6% below the Medical Diagnostics & Research industry median of 68.88. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current Days Inventory is 6.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
Days Inventory: 6.48 (114% above median its 10-year median of 3.03)
GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
Industry Position: 90.6% below the Medical Diagnostics & Research median (#7 of 178)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
